Sector News

Italy's Dompe Farmaceutici mulls listing as part of shift to biotech

October 26, 2018
Life sciences

Family-owned Italian biopharmaceutical group Dompe Farmaceutici is considering a listing of its shares as it looks to focus more on its biotech business and treating specific diseases.

“In 3-4 years we could consider a flotation perhaps in the U.S.,” Chief Executive Sergio Dompe said.

Dompe, son of company founder Franco Dompe, said other options also existed, including a reverse merger – or buying a listed business – in the United States, one of the company’s key markets.

The CEO said private equity firms, as well as some European and U.S. industrial players, had made contact with a view to buying the company.

“I told them not to bother since I will never sell,” he said.

Italy has a thriving pharmaceutical sector. But it is fragmented and analysts believe it could benefit from consolidation.

In June, family-controlled Recordati was snapped up by a consortium of investment funds controlled by CVC Capital Partners in a deal worth about 3 billion euros ($3.4 billion).

Dompe Farmaceutici, headquartered in Milan, employs around 800 people and had sales last year of 250 million euros.

Six patients dead after New Jersey virus outbreak
Earlier this year the U.S. Food and Drug Administration approved its new product based on cenegermin – the first drug for the treatment of rare eye disease neurotrophic keratitis.

Dompe, who hopes to be able to market the new treatment in China, said the new cenegermin-based drug was a game changer that could help boost margins over time and support investments in research and development.

“I’m looking to make this company a pharmaceutical biotech business with a focus on particular diseases,” Dompe said. ($1 = 0.8786 euros)

By Stephen Jewkes

Source: Reuters

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach